Targeted Immune Profiling MIODx specializes in profiling an individual’s adaptive immune system over time using the ClonoMap platform, presenting an opportunity to position its immune repertoire insights to pharma and biotech firms exploring prognostic tools and personalized therapies.

Cloud Collaboration ClonoMap Immune Profiler on DNAnexus Titan enables secure project and data sharing among authorized team members, highlighting a potential sales angle with cloud-enabled collaboration and data governance features for CROs and large research teams.

Early Revenue Path With current revenue under one million and external funding of 1.5 million, MIODx is at an early-growth stage, suggesting opportunities to engage investors and strategic partners seeking innovative immune profiling capabilities.

Startup Scale Fit Small team size (2-10 employees) paired with a market landscape of large biotech players indicates a fit for enterprise partnerships or pilot collaborations that leverage MIODx’s niche ClonoMap capabilities without requiring extensive integration from the outset.

Clinical and Diagnostic Relevance The focus on T cell diversity as a prognostic tool aligns with trends in oncology and infectious disease diagnostics, creating openings to align with diagnostics developers, companion diagnostic programs, and clinical trial collaborators seeking predictive immune biomarkers.